Drugs Controller General of India (DCGI) on Friday gave permission to Bharat Biotech for intranasal booster dose trials against COVID-19.The trials will be conducted at nine different sites. The development came a day after Bharat Biotech's COVID-19 vaccine COVAXIN, along with the Serum Institute of India's (SII) Covishield, granted regular market approval for use in the adult population.

Tweet By ANI:

(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)